New Hope for Ovarian Cancer: Lixte's Drug Combo Shows Early Promise

SAN JUAN, PR – April 13, 2026 – New data presented at a major oncology conference has ignited a spark of hope for patients with a notoriously difficult-to-treat form of ovarian cancer. LIXTE Biotechnology Holdings, Inc. announced favorable preliminary results from a clinical trial combining its proprietary compound, LB-100, with the immunotherapy drug Dostarlimab. The findings, unveiled at the 2026 Conference of the Society of Gynecological Cancer, suggest a potential new path forward for patients with ovarian clear cell carcinoma (OCCC), a disease with few effective therapeutic options.

The Challenge of a Chemo-Resistant Cancer

Ovarian clear cell carcinoma, while accounting for only 5-10% of ovarian cancers, is a particularly aggressive and challenging subtype. Unlike more common forms of ovarian cancer, OCCC is often resistant to the standard-of-care platinum-based chemotherapy, leading to a significantly poorer prognosis. This inherent resistance has created a profound unmet medical need, leaving clinicians and patients searching for new strategies to combat the disease, especially when it is advanced or has recurred.

Recent research has begun to unravel the molecular complexities of OCCC. Scientists have identified that mutations in a specific gene, PPP2R1A, can make these tumors more responsive to immune checkpoint inhibitors (ICIs), a class of drugs that helps the body's immune system recognize and attack cancer. However, these beneficial mutations are not present in all patients, leaving a large portion of women with OCCC without this potential advantage. The central challenge, therefore, has been to find a way to make immunotherapy effective for the broader OCCC patient population.

A Novel Strategy to 'Activate' the Immune System

This is where LIXTE's innovative approach comes into play. The clinical trial, sponsored by The University of Texas MD Anderson Cancer Center, is built on a compelling scientific hypothesis. It combines GSK’s Dostarlimab, a PD-1 blocking antibody designed to unleash the immune system, with LIXTE’s LB-100, a first-in-class inhibitor of a protein called PP2A.

The trial's lead investigator, Dr. Amir Jazaeri, Professor of Gynecologic Oncology at MD Anderson, has previously observed that a natural, genetic reduction in PP2A activity correlates with a better response to immunotherapy. The current study aims to replicate this effect pharmacologically using LB-100.

“We are learning more about the molecular features of ovarian clear-cell carcinomas that correlate with benefit from immune checkpoint inhibitors,” said Dr. Jazaeri in the company's press release. “This study investigates how to use immunotherapy combinations such as Dostarlimab and LB-100 to expand the benefit for patients whose tumors do not carry these features.”

By inhibiting PP2A, LB-100 is believed to make cancer cells more vulnerable and, crucially, to stimulate an immune response. This concept, which LIXTE pioneers as 'activation lethality,' could effectively turn immunologically 'cold' tumors—those invisible to the immune system—into 'hot' tumors that can be targeted and destroyed. The goal is to give patients without the beneficial PPP2R1A mutation the same chance at a powerful immunotherapy response.

Encouraging Early Signals from the Trial

The preliminary data presented from the Phase 1b/2 trial (NCT06065462) provides the first clinical validation of this strategy in OCCC. In the initial cohort of 21 patients, the combination of LB-100 and Dostarlimab demonstrated an acceptable safety profile. For the 20 patients evaluated for efficacy, the results were encouraging.

At a median follow-up of 12 months, the median overall survival (OS) had not yet been reached—a positive sign in early-stage oncology trials, as it indicates a significant portion of patients are living longer than expected. The probability of survival was 84% at six months and 69% at 12 months. Furthermore, the Disease Control Rate (DCR), which includes patients whose tumors shrank or remained stable, was 40%.

“The findings being presented provide new hope for patients with ovarian cancer, a disease that thus far has limited therapeutic options,” stated Bas van der Baan, LIXTE’s Chief Scientific Officer. “Based on those favorable results, an additional cohort of 21 patients with a higher exposure to LB-100 is in the process of enrolling.”

This trial expansion is a key indicator of the confidence researchers have in the drug combination's potential and safety, as they seek to optimize the dosage of LB-100 to maximize its therapeutic effect.

Lixte's Position in a Competitive Landscape

For LIXTE Biotechnology (Nasdaq: LIXT), a clinical-stage company, these results represent a significant milestone. The company has positioned LB-100 as a foundational 'plug-and-play' therapy that can enhance a wide range of existing cancer treatments, from chemotherapy to immunotherapy. Success in OCCC could serve as powerful proof-of-concept for this 'activation lethality' platform, potentially de-risking its development in other difficult-to-treat cancers, including ongoing trials in metastatic colon cancer and advanced soft tissue sarcoma.

The oncology market is fiercely competitive, but the high unmet need in OCCC provides a clear opportunity. While immunotherapy has transformed treatment for some cancers, its success in unselected ovarian cancer populations has been limited. The failure of other major trials to show a significant overall survival benefit with immunotherapies in this space underscores the need for novel combination strategies like LIXTE's. By focusing on a mechanism to sensitize tumors to immunotherapy, LIXTE is carving out a unique niche that could complement, rather than compete with, the arsenals of major pharmaceutical companies.

With a comprehensive patent portfolio protecting its novel approach, LIXTE is poised to advance a new treatment paradigm. While the data is still early and longer-term follow-up is necessary, these preliminary findings offer a scientifically grounded reason for cautious optimism, suggesting that a new chapter may be opening for women battling this formidable disease.